Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
- ID
- 6285
- Status
- summarized
- Published
- 21 Jul 2026, 7:39 AM
- Fetched
- 21 Jul 2026, 8:31 AM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/07/20/colossal-biosciences-reportedly-in-talks-to-raise-new-capital-at-20b-30b-valuation/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 5.5
- Created
- 21 Jul 2026, 8:31 AM
- Tags
- Audience
- startup-foundersai-ml-learners
What happened
Colossal Biosciences, a startup focused on de-extinction, is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion, potentially doubling or tripling its previous valuation. The deal signals continued investor appetite for ambitious, science-heavy frontier startups despite broader market caution.
Why it matters
For Malaysian and Southeast Asian startup founders and builders, this is a useful data point on how deep-tech, high-risk ventures can still command outsized valuations if the narrative and scientific ambition are compelling enough. It also highlights the growing intersection of biotech, AI, and computational biology—areas where regional builders could find niche opportunities, partnerships, or talent demand.
Discussion angle
What does the willingness to fund a $20B+ de-extinction startup tell us about how investors price narrative and scientific ambition versus traction—and how can Southeast Asian founders apply that lens to pitching frontier or deep-tech ideas?